The move comes weeks after Pfizer terminated its partnership with Sangamo Therapeutics for another hemophilia gene therapy.

The hemophilia market is expected to experience significant growth due to advancements in gene therapy, innovative treatments, and an increasing focus on personalized medicine. Rising awareness and ...

Altuvoct (efanesoctocog alfa) was approved in the U.K. as a treatment for patients with moderate or severe hemophilia A ages ...

Sobi’s Sanofi-partnered efanesoctocog alfa has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA ...

The government has set aside £11.8bn to compensate victims of the infected blood scandal, after a public inquiry found the ...

Antibody therapy Mim8 was found to be safe and effective for controlling bleeds in children with hemophilia A in a Phase 3 ...

Novo Nordisk today announced interim results from the phase 3 FRONTIER3 trial of 70 children (aged 1-11 years old) with haemophilia A with and without inhibitors. The trial initially assessed ...

Novo Nordisk’s haemophilia A therapy Mim8 stopped bleeding completely in 74.3% of children in a Phase III trial. The ...

Novo Nordisk today announced interim results from the phase 3 FRONTIER3 trial of 70 children (aged 1-11 years old) with haemophilia A with and without inhibitors. The trial initially assessed ...

Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis experienced zero treated ...

Haemophilia A, which is caused by a missing or defective clotting factor VIII, accounts for up to 85% of global cases, and it is estimated that up to 30% of patients with this form of the disease have ...